- Reaction score
- 122
at least something to work towards and save up for if you have a good job its doable. however indeed not for the average person as in average salary around the world
Stemson is going to use minipigs in the next stage of their hair cloning research
- Thread starter werefckd
- Start date
ok, i agree but not for 50k, this will be a lot more expensive
- Reaction score
- 122
thatd nake no sense busibess wise. people overstimate rhe number od rich people who cant afford elon musk like transplant anyway who would undergo a completely now and no rigorously tested procedure, most people with such a fortune do jot even bother getting a transplant or use finasteride. stemsons market would be very small, why do you think they are working on improving the procedure, so they can offer it to like 15 people and not even earn their investmenr back? this is complete nonsense
I would like it to be as you write, but knowing life, they will want as much as Tsuji, if they see that there are peoplem willing to pay for it, the price will be high, and the average joe will wait another 10 years
- Reaction score
- 122
thankfully you are not in business but just a guy who posts on HairLossTalk.com
it would be great for me too if i had to pay 50k $ for new hair
We do not know.
Stem cells from the bioreactor
With the aid of artificial stem cells, it will soon be possible to establish new treatments for previously incurable diseases such as Alzheimer's disease. At the Fraunhofer Project Center for Stem Cell Process Engineering SPT, a process for the mass production of these so called induced pluripotent stem cells is being developed.
This process involves new materials, which ensure that industrial cell production will meet high quality standards. The process will be unveiled to the public for the first time at the MEDICA trade fair in Düsseldorf, Germany, between November 15 and 18, 2021 (hall 3, stand E74).
The cells of a growing embryo have a fascinating property. They are able to transform into any other cell type – heart muscle cells, nerve cells and many more. Experts refer to them as pluripotent stem cells. When the human body is fully developed, the cells lose their pluripotency. Recently, however, it has become possible to artificially revert the somatic cells of an adult to their embryonic state. These "induced pluripotent stem cells" (iPS) are an important tool for biotechnologists. This means that somatic cells can be taken from adults with genetic diseases, reprogrammed into iPS cells and then differentiated into heart muscle or nerve cells, which can then be used to test new drugs. Because the iPS cells contain the patient's genome, it's much easier to determine which treatments will be effective for that patient. In this respect, iPS cells have huge potential for personalized medicine. The problem is that thus far, it hasn't been possible to produce iPS cells and culture them in large quantities and to a high quality. There lacks a standardized production line and process for industrial manufacturing that meets regulatory requirements. The new Fraunhofer Project Center for Stem Cell Process Engineering SPT in Würzburg, which is jointly operated by the Fraunhofer Institute for Biomedical Engineering IBMT and the Fraunhofer Institute for Silicate Research ISC, is working on exactly that.
"In this project, we're combining our biotechnology expertise with the materials science know-how," says the Managing Director of SPT, Julia Neubauer of the Fraunhofer IBMT. The Fraunhofer ISC is sharing its vast experience in the development of materials and surface coatings to help optimize the Fraunhofer IBMT biotechnologies for cell culture at the project center. Around the world, most scientists currently use hard, smooth surfaces for cell culture. On this type of surface, cells such as artificial heart muscle cells that actually contract can be grown. They do, however, behave differently to cells in a living body. For example, they hardly react to hormones such as adrenaline, which should make them beat faster. The SPT team is creating more realistic culture conditions so that the iPS cells will develop into more mature cells that behave naturally. Instead of hard surfaces, soft surface coatings made of hydrogels and 3D "biomimetic structures" made with 3D printers are used, for example. The surfaces are also modified with biochemical processes so that tissue-specific environment can be simulated.
The key to iPS cell culture at SPT is the use of bioreactors, in which the cells grow while floating freely in a nutrient solution or adherent on microcarrier. Julia Neubauer and Marco Metzger of the Fraunhofer ISC, the SPT's Deputy Managing Director, explain that in these reactors, the cells are cultured on tiny hydrogel microspheres, for example. They can also grow in small 3D aggregates and interact with each other. These methods successfully mimic natural tissue growth. Another advantage of free-floating iPS cell culture is that the cells receive optimal nutrition and oxygen. In a group of cells on a 2D surface, those on the bottom layer are often less well nourished. The cell environment also doesn't provide natural conditions.
Manufacturing stem cells in a bioreactor
With the aid of artificial stem cells, it will soon be possible to establish new treatments for previously incurable diseases such as Alzheimer's disease. At the Fraunhofer Project Center for Stem Cell Process Engineering SPT, a process for the mass production of these so called induced...
Stem cells from the bioreactor
With the aid of artificial stem cells, it will soon be possible to establish new treatments for previously incurable diseases such as Alzheimer’s disease.
Homepage Fraunhofer-Gesellschaft
The Fraunhofer-Gesellschaft, based in Germany, is a leading applied research organization. It plays a crucial role in the innovation process by prioritizing research in key future technologies and transferring its research findings to industry in order to strengthen Germany as a hub of...
www.fraunhofer.de
- Reaction score
- 1,104
Just want to remember everyone that the ipsc-therapies summit is taking place in a few weeks.
Stemson will be there too and they will be talking about the; "[...] differentiation protocols and [...] cell purity to unveil the full potential of iPSCs (with Stemson Therapeutics) [...]"
ipsc-therapies-summit.com
Stemson will be there too and they will be talking about the; "[...] differentiation protocols and [...] cell purity to unveil the full potential of iPSCs (with Stemson Therapeutics) [...]"
Full Event Guide | iPSC Drug Development & Manufacturing Summit
Less than 4 weeks remain until 80+ iPSC senior level experts converge in Boston to discuss the largest challenges to iPSC development.
ipsc-therapies-summit.com
- Reaction score
- 292
are they going to live stream? hopefully someone can record and upload it hereJust want to remember everyone that the ipsc-therapies summit is taking place in a few weeks.
Stemson will be there too and they will be talking about the; "[...] differentiation protocols and [...] cell purity to unveil the full potential of iPSCs (with Stemson Therapeutics) [...]"
Full Event Guide | iPSC Drug Development & Manufacturing Summit
Less than 4 weeks remain until 80+ iPSC senior level experts converge in Boston to discuss the largest challenges to iPSC development.
- Reaction score
- 1,104
Access is pretty much restricted to companies and so on, soo. Yeah, no.
- Reaction score
- 1,104
DAY TWO - of IPSC-summit event:
"10:30 am Strategies to Improve Differentiation of iPS Cells to Targeted End-Fate CellsGeoff HamiltonCo-Founder & CEO, Stemson Therapeutics
SynopsisConsistent, efficient and high yield differentiation of iPS cells to the targeted cell types is difficult to achieveThis talk will review strategies to improve differentiation including genomic and proteomic analysis techniques and in vitro modeling"
"11:30 am Panel Discussion: Exploring How to Refine Differentiation Protocols for Successful Generation of Target Immune CellsKeiichi FukudaCEO, HeartseedGeoff HamiltonCo-Founder & CEO, Stemson TherapeuticsGregory FiorePresident & CEO, Exacis Biotherapeutics
SynopsisAchieving successful differentiation with minimal optimization of multiple patient iPSC linesExploring techniques to remove function inhibiting small molecules in final stages of differentiation to enhance the function of differentiated cellsDiscussing how to achieve a very high yield consistent output at the end of the protocol and how to control thisHow to confirm that the differentiated cells meets the definition of the target differentiated cells"
"3:30 pm Panel Discussion: Developing an Early Commercialization Strategy for an iPSC-Derived TherapyGeoff HamiltonCo-Founder & CEO, Stemson TherapeuticsDavid MainCEO, Notch TherapeuticsKillian KellyCOO, Cynata Therapeutics
SynopsisExploring future affordability of iPSC-derived products to patients in need and potential reimbursement strategiesObtaining approval from the agencies – what are their key expectationsThe importance of standardizing manufacturing platforms for successful commercialization"
ipsc-therapies-summit.com
The topics where Stemson Therapeutics will hold a speech are quite interesting... Hope we will get a little insight
"10:30 am Strategies to Improve Differentiation of iPS Cells to Targeted End-Fate CellsGeoff HamiltonCo-Founder & CEO, Stemson Therapeutics
SynopsisConsistent, efficient and high yield differentiation of iPS cells to the targeted cell types is difficult to achieveThis talk will review strategies to improve differentiation including genomic and proteomic analysis techniques and in vitro modeling"
"11:30 am Panel Discussion: Exploring How to Refine Differentiation Protocols for Successful Generation of Target Immune CellsKeiichi FukudaCEO, HeartseedGeoff HamiltonCo-Founder & CEO, Stemson TherapeuticsGregory FiorePresident & CEO, Exacis Biotherapeutics
SynopsisAchieving successful differentiation with minimal optimization of multiple patient iPSC linesExploring techniques to remove function inhibiting small molecules in final stages of differentiation to enhance the function of differentiated cellsDiscussing how to achieve a very high yield consistent output at the end of the protocol and how to control thisHow to confirm that the differentiated cells meets the definition of the target differentiated cells"
"3:30 pm Panel Discussion: Developing an Early Commercialization Strategy for an iPSC-Derived TherapyGeoff HamiltonCo-Founder & CEO, Stemson TherapeuticsDavid MainCEO, Notch TherapeuticsKillian KellyCOO, Cynata Therapeutics
SynopsisExploring future affordability of iPSC-derived products to patients in need and potential reimbursement strategiesObtaining approval from the agencies – what are their key expectationsThe importance of standardizing manufacturing platforms for successful commercialization"
4th iPSC Drug Development & Manufacturing Summit | Boston, MA
View the agenda to see what's on over this two day conference. Find out more on session details, session times, speakers and more.
ipsc-therapies-summit.com
The topics where Stemson Therapeutics will hold a speech are quite interesting... Hope we will get a little insight
Stemson's R&D team keeps growing. There are 13 people in it now, compared to I think 7 at the beginning of this year. This is a good sign, and they still have open job listings so we can expect the company will keep growing.
The more people we have working at this problem, the bigger the chances they will succeed.
I wish the best luck to them!
The more people we have working at this problem, the bigger the chances they will succeed.
I wish the best luck to them!
The more people working there, the higher are the chances they will deliver the cure. That’s the point.
Nah. We’re fucked!
Would this be the answer for us with dupa as people with dupa cant have a hairtransplant.but saying that ive had a hairtransplant though last year but now apparently he says I suddenly developed hairloss a few months ago.ive been on finasteride for over 12 years and was working great as far as I could tell.
Last edited:
- Reaction score
- 292
Yes because it doesn’t matter what degree of hairloss you have . The state of your hairloss does not mean anything for the hair follicles they produce for transplant
Well that's great news because apparently the donor is susceptible to dht in dupa so where would they take healthy hairs from to clone them?I've read the entire thread but must have missed that part